Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 5/20 | 0.50 |
| ▸ | NAAA | Q02083 | 3/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 9/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | BACH1 | O14867 | 1/20 | 0.44 |
| ▸ | MAFK | O60675 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25335000 | 0.84 | — | — | |
| Butyl Isothiocyanate SCHEMBL4633771 | 0.82 | NAAA (0.55) | MIFNAAATRPA1KEAP1NFE2L2 | |
| SCHEMBL30102642 | 0.80 | NAAA (0.58) | MIFNAAATRPA1KEAP1NFE2L2 | |
| SCHEMBL30102626 | 0.80 | NAAA (0.58) | MIFNAAATRPA1KEAP1NFE2L2 | |
| SCHEMBL21707528 | 0.78 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL27551593 | 0.77 | NAAA (0.54) | MIFNAAATRPA1KEAP1NFE2L2 | |
| SCHEMBL27551595 | 0.77 | NAAA (0.54) | MIFNAAATRPA1KEAP1NFE2L2 | |
| SCHEMBL484045 | 0.75 | MIF (0.68) | MIFNAAATRPA1KEAP1NFE2L2 | |
| SCHEMBL1021255 | 0.75 | — | — | |
| SCHEMBL7133119 | 0.72 | NAAA (0.74) | MIFNAAATRPA1KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366551-A1 | MIXTURES AND COMPOSITIONS COMPRISING SULFORAPHANE AND GLYCINE | NESTLE SA (CH) | 2024-11-07 | — | — | US | claimed |
| EP-4387604-A1 | MIXTURES AND COMPOSITIONS COMPRISING SULFORAPHANE AND GLYCINE | Société des Produits Nestlé S.A. (CH) | 2024-06-26 | — | — | EP | claimed |
| CN-117979963-A | Mixtures and compositions comprising sulforaphane and glycine | 雀巢产品有限公司 | 2024-05-03 | — | — | CN | claimed |
| WO-2023021040-A1 | MIXTURES AND COMPOSITIONS COMPRISING SULFORAPHANE AND GLYCINE | Société des Produits Nestlé S.A. (CH) | 2023-02-23 | — | — | WO | claimed |
| EP-2854862-B1 | SULFORAPHANE ISOLATION AND PURIFICATION | PHARMAGRA LABS INC (US) | 2018-08-01 | — | — | EP | claimed |
| EP-1313377-B1 | TREATMENT OF HELICOBACTER WITH ISOTHIOCYANATES | FAHEY JED W (US) | 2015-01-21 | — | — | EP | claimed |
| EP-2796140-A2 | Stabilized Sulforaphane | Pharmagra Labs, Inc. (US) | 2014-10-29 | — | — | EP | claimed |
| EP-2532352-A1 | Stabilized Sulforaphane | Pharmagra Labs, Inc. (US) | 2012-12-12 | — | — | EP | claimed |
| US-20120258060-A1 | METHODS FOR PROTECTING THE SKIN FROM RADIATION INSULTS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-10-11 | — | — | US | claimed |
| EP-1890683-B1 | METHODS OF SUPRESSING UV LIGHT-INDUCED SKIN CARCINOGENESIS | UNIV JOHNS HOPKINS (US) | 2011-06-08 | — | — | EP | claimed |
| US-20080176942-A1 | Stabilized sulforaphane | PHARMAGRA LABS, INC. (US) | 2008-07-24 | — | — | US | claimed |
| EP-1890683-A1 | METHODS OF SUPRESSING UV LIGHT-INDUCED SKIN CARCINOGENESIS | Johns Hopkins University (US) | 2008-02-27 | — | — | EP | claimed |
| WO-2006118941-A1 | METHODS OF SUPRESSING UV LIGHT-INDUCED SKIN CARCINOGENESIS | JOHNS HOPKINS UNIVERSITY (US) | 2006-11-09 | — | — | WO | claimed |
| US-6812248-B2 | Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes | JOHN HOPKINS UNIVERSITY SCHOOL OF MEDICINE | 2004-11-02 | — | — | US | claimed |
| US-20020091087-A1 | Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes | JOHNS HOPKINS UNIVERSITY | 2002-07-11 | — | — | US | claimed |
| WO-2002002190-A2 | PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES BY GLUTATHIONE AND PHASE II DETOXIFICATION ENZYMES | JOHNS HOPKINS SCHOOL OF MEDICINE (US) | 2002-01-10 | — | — | WO | claimed |
| US-RE36784-E | Chemoprotective isothiocyanates | THE JOHNS HOPKINS UNIVERSITY (US) | 2000-07-18 | — | — | US | claimed |
| US-5411986-A | Chemoprotective isothiocyanates | THE JOHNS HOPKINS UNIVERSITY (US) | 1995-05-02 | — | — | US | claimed |
| WO-1994019948-A9 | CHEMOPROTECTIVE ISOTHIOCYANATES | — | 1994-11-10 | — | — | WO | claimed |
| WO-1994019948-A1 | CHEMOPROTECTIVE ISOTHIOCYANATES | CHO CHEON GYU (US) | 1994-09-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258060-A1 | METHODS FOR PROTECTING THE SKIN FROM RADIATION INSULTS | GSTK1, NFE2L2, NQO1 | MIF 691/4885NAAA 3823/4885TRPA1 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.